{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T23:35:11Z","timestamp":1782862511954,"version":"3.54.5"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,6,22]],"date-time":"2024-06-22T00:00:00Z","timestamp":1719014400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,6,22]],"date-time":"2024-06-22T00:00:00Z","timestamp":1719014400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Medical Research Future Fund","award":["2007155"],"award-info":[{"award-number":["2007155"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>There are no approved pharmacotherapies for methamphetamine use disorder. Two preliminary phase 2 randomised controlled trials have found mirtazapine, a tetracyclic antidepressant, to be effective in reducing methamphetamine use. The proposed Tina Trial is the first phase 3 placebo-controlled randomised trial to examine the effectiveness and safety of mirtazapine as an outpatient pharmacotherapy for methamphetamine use disorder.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This is a multi-site phase 3 randomised, double-blind, placebo-controlled parallel trial. Participants are randomly allocated (1:1) to receive either mirtazapine (30\u00a0mg\/day for 12\u00a0weeks) or matched placebo, delivered as a take-home medication. The target population is 340 people aged 18\u201365\u00a0years who have moderate to severe methamphetamine use disorder. The trial is being conducted through outpatient alcohol and other drug treatment clinics in Australia. The primary outcome is measured as self-reported days of methamphetamine use in the past 4\u00a0weeks at week 12. Secondary outcomes are methamphetamine-negative oral fluid samples, depressive symptoms, sleep quality, HIV risk behaviour and quality of life. Other outcomes include safety (adverse events), tolerability, and health service use. Medication adherence is being monitored using MEMS\u00ae Smart Caps fitted to medication bottles.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Discussion<\/jats:title>\n                <jats:p>This trial will provide information on the safety and effectiveness of mirtazapine as a pharmacotherapy for methamphetamine use disorder when delivered as an outpatient medication in routine clinical practice. If found to be safe and effective, this trial will support an application for methamphetamine use disorder to be included as a therapeutic indication for the prescription of mirtazapine.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>Australian and New Zealand Clinical Trials Registry ACTRN12622000235707. Registered on February 9, 2022.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13063-024-08238-y","type":"journal-article","created":{"date-parts":[[2024,6,22]],"date-time":"2024-06-22T01:01:59Z","timestamp":1719018119000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["A phase 3 randomised double-blind placebo-controlled trial of mirtazapine as a pharmacotherapy for methamphetamine use disorder: a study protocol for the Tina Trial"],"prefix":"10.1186","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2833-4830","authenticated-orcid":false,"given":"Rebecca","family":"McKetin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tayla J.","family":"Degan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy","family":"Saunders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Long","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Dore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Shoptaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Farrell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louisa","family":"Degenhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J.","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alyna","family":"Turner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip J.","family":"Clare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia M.","family":"Dean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shalini","family":"Arunogiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Colledge-Frisby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juanita","family":"Koeijers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Goodman-Meza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Sinclair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Reid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry","family":"Hill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy","family":"Hayllar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Christmass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Cordaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Lundin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Willy","family":"Liaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danica","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellie","family":"Holyoak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian Tid-Fung","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel","family":"Keygan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ava","family":"Kontogiannis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lily","family":"Palmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caity","family":"Morrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Wrobel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bec","family":"Hyland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne","family":"Byrne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Russell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Zahra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Berk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,22]]},"reference":[{"key":"8238_CR1","doi-asserted-by":"crossref","unstructured":"Degenhardt L, Larney S, Dobbins T, Chan G, Weier M, Roxburgh A, et al. Estimating the number of regular and dependent methamphetamine users in Australia, 2002\u20132014. Med J Aust. 2016;204(4):153.","DOI":"10.5694\/mja15.00671"},{"key":"8238_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2021.108750","volume":"225","author":"JC Strickland","year":"2021","unstructured":"Strickland JC, Stoops WW, Dunn KE, Smith KE, Havens JR. The continued rise of methamphetamine use among people who use heroin in the United States. Drug Alcohol Depend. 2021;225: 108750.","journal-title":"Drug Alcohol Depend"},{"key":"8238_CR3","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1111\/j.1360-0443.2012.03933.x","volume":"107","author":"R McKetin","year":"2012","unstructured":"McKetin R, Najman J, Baker A, Lubman D, Dawe S, Ali R, et al. Evaluating the impact of community-based treatment options on methamphetamine use: findings from the Methamphetamine Treatment Evaluation Study (MATES). Addiction. 2012;107:1998\u20132008.","journal-title":"Addiction"},{"issue":"10209","key":"8238_CR4","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1016\/S0140-6736(19)32230-5","volume":"394","author":"M Farrell","year":"2019","unstructured":"Farrell M, Martin NK, Stockings E, Borquez A, Cepeda JA, Degenhardt L, et al. Responding to global stimulant use: challenges and opportunities. Lancet (London, England). 2019;394(10209):1652\u201367.","journal-title":"Lancet (London, England)"},{"issue":"2","key":"8238_CR5","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1111\/dar.12518","volume":"37","author":"R McKetin","year":"2018","unstructured":"McKetin R, Degenhardt L, Shanahan M, Baker AL, Lee NK, Lubman DI. Health service utilisation attributable to methamphetamine use in Australia: Patterns, predictors and national impact. Drug Alcohol Rev. 2018;37(2):196\u2013204.","journal-title":"Drug Alcohol Rev"},{"issue":"12","key":"8238_CR6","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1001\/jamapsychiatry.2021.2588","volume":"78","author":"B Han","year":"2021","unstructured":"Han B, Compton WM, Jones CM, Einstein EB, Volkow ND. Methamphetamine Use, Methamphetamine Use Disorder, and Associated Overdose Deaths Among US Adults. JAMA Psychiat. 2021;78(12):1329\u201342.","journal-title":"JAMA Psychiat"},{"issue":"5","key":"8238_CR7","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1111\/dar.12048","volume":"32","author":"M Brensilver","year":"2013","unstructured":"Brensilver M, Heinzerling KG, Shoptaw S. Pharmacotherapy of amphetamine-type stimulant dependence: An update. Drug Alcohol Rev. 2013;32(5):449\u201360.","journal-title":"Drug Alcohol Rev"},{"issue":"9739","key":"8238_CR8","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/S0140-6736(10)60753-2","volume":"376","author":"G Colfax","year":"2010","unstructured":"Colfax G, Santos G-M, Chu P, Vittinghoff E, Pluddemann A, Kumar S, et al. Amphetamine-group substances and HIV. Lancet (London, England). 2010;376(9739):458\u201374.","journal-title":"Lancet (London, England)"},{"key":"8238_CR9","doi-asserted-by":"crossref","unstructured":"Ezard N, Dunlop A, Clifford B, Bruno R, Carr A, Bissaker A, et al. Study protocol: A dose-escalating, phase-2 study of oral lisdexamfetamine in adults with methamphetamine dependence. BMC Psychiatry. 2016;16(1):428.","DOI":"10.1186\/s12888-016-1141-x"},{"issue":"2","key":"8238_CR10","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1056\/NEJMoa2020214","volume":"384","author":"MH Trivedi","year":"2021","unstructured":"Trivedi MH, Walker R, Ling W, Dela Cruz A, Sharma G, Carmody T, et al. Bupropion and Naltrexone in Methamphetamine Use Disorder. N Engl J Med. 2021;384(2):140\u201353.","journal-title":"N Engl J Med"},{"key":"8238_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2021.101005","volume":"38","author":"R McKetin","year":"2021","unstructured":"McKetin R, Dean OM, Turner A, Kelly PJ, Quinn B, Lubman DI, et al. N-acetylcysteine (NAC) for methamphetamine dependence: A randomised controlled trial. EClinicalMedicine. 2021;38: 101005.","journal-title":"EClinicalMedicine"},{"issue":"2","key":"8238_CR12","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1111\/add.16347","volume":"119","author":"H Sharafi","year":"2024","unstructured":"Sharafi H, Bakouni H, McAnulty C, Drouin S, Coronado-Montoya S, Bahremand A, et al. Prescription psychostimulants for the treatment of amphetamine-type stimulant use disorder: A systematic review and meta-analysis of randomized placebo-controlled trials. Addiction. 2024;119(2):211\u201324.","journal-title":"Addiction"},{"issue":"1","key":"8238_CR13","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.drugalcdep.2006.03.005","volume":"85","author":"S Shoptaw","year":"2006","unstructured":"Shoptaw S, Huber A, Peck J, Yang X, Liu J, Jeff D, et al. Randomized, placebo-controlled trial of sertraline and contingency management for the treatment of methamphetamine dependence. Drug Alcohol Depend. 2006;85(1):12\u20138.","journal-title":"Drug Alcohol Depend"},{"issue":"11","key":"8238_CR14","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1001\/archgenpsychiatry.2011.124","volume":"68","author":"GN Colfax","year":"2011","unstructured":"Colfax GN, Santos GM, Das M, Santos DM, Matheson T, Gasper J, et al. Mirtazapine to reduce methamphetamine use: A randomized controlled trial. Arch Gen Psychiatry. 2011;68(11):1168\u201375.","journal-title":"Arch Gen Psychiatry"},{"issue":"3","key":"8238_CR15","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1001\/jamapsychiatry.2019.3655","volume":"77","author":"PO Coffin","year":"2019","unstructured":"Coffin PO, Santos GM, Hern J, Vittinghoff E, Walker JE, Matheson T, et al. Effects of Mirtazapine for Methamphetamine Use Disorder Among Cisgender Men and Transgender Women Who Have Sex With Men: A Placebo-Controlled Randomized Clinical Trial. JAMA Psychiat. 2019;77(3):246\u201355.","journal-title":"JAMA Psychiat"},{"key":"8238_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2022.109295","volume":"232","author":"L Naji","year":"2022","unstructured":"Naji L, Dennis B, Rosic T, Wiercioch W, Paul J, Worster A, et al. Mirtazapine for the treatment of amphetamine and methamphetamine use disorder: A systematic review and meta-analysis. Drug Alcohol Depend. 2022;232: 109295.","journal-title":"Drug Alcohol Depend"},{"issue":"3","key":"8238_CR17","doi-asserted-by":"publisher","first-page":"200","DOI":"10.7326\/0003-4819-158-3-201302050-00583","volume":"158","author":"AW Chan","year":"2013","unstructured":"Chan AW, Tetzlaff JM, Altman DG, Laupacis A, G\u00f8tzsche PC, Krle\u017ea-Jeri\u0107 K, et al. SPIRIT 2013 statement: defining standard protocol items for clinical trials. Ann Intern Med. 2013;158(3):200\u20137.","journal-title":"Ann Intern Med"},{"key":"8238_CR18","doi-asserted-by":"crossref","unstructured":"American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 5th\u00a0ed. Arlington, VA: American Psychiatric Association; 2013.","DOI":"10.1176\/appi.books.9780890425596"},{"issue":"1","key":"8238_CR19","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1037\/0022-006X.68.1.134","volume":"68","author":"W Fals-Stewart","year":"2000","unstructured":"Fals-Stewart W, O\u2019Farrell TJ, Freitas TT, McFarlin SK, Rutigliano P. The timeline followback reports of psychoactive substance use by drug-abusing patients: psychometric properties. J Consult Clin Psychol. 2000;68(1):134\u201344.","journal-title":"J Consult Clin Psychol"},{"key":"8238_CR20","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1196\/annals.1384.038","volume":"1098","author":"MA Huestis","year":"2007","unstructured":"Huestis MA, Cone EJ. Methamphetamine Disposition in Oral Fluid, Plasma, and Urine. Ann N Y Acad Sci. 2007;1098:104\u201321.","journal-title":"Ann N Y Acad Sci"},{"issue":"9","key":"8238_CR21","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1046\/j.1525-1497.2001.016009606.x","volume":"16","author":"K Kroenke","year":"2001","unstructured":"Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001;16(9):606\u201313.","journal-title":"J Gen Intern Med"},{"issue":"6","key":"8238_CR22","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/S0022-3999(00)00095-7","volume":"48","author":"CR Soldatos","year":"2000","unstructured":"Soldatos CR, Dikeos DG, Paparrigopoulos TJ. Athens Insomnia Scale: validation of an instrument based on ICD-10 criteria. J Psychosom Res. 2000;48(6):555\u201360.","journal-title":"J Psychosom Res"},{"issue":"5","key":"8238_CR23","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1111\/j.1360-0443.1992.tb02719.x","volume":"87","author":"S Darke","year":"1992","unstructured":"Darke S, Hall W, Wodak A, Heather N, Ward J. Development and validation of a multi-dimensional instrument for assessing outcome of treatment among opiate users: the Opiate Treatment Index. Br J Addict. 1992;87(5):733\u201342.","journal-title":"Br J Addict"},{"issue":"10","key":"8238_CR24","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","volume":"20","author":"M Herdman","year":"2011","unstructured":"Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res. 2011;20(10):1727\u201336.","journal-title":"Qual Life Res"},{"key":"8238_CR25","unstructured":"Posner K, Brent D, Lucas C, Gould M, Stanley B, Brown G, et al. Columbia-Suicide severity rating scale (C-SSRS) Version 6. The Research Foundation for Mental Hygiene, Inc; New York; 2008."},{"issue":"16","key":"8238_CR26","first-page":"1","volume":"52","author":"J Bjureberg","year":"2021","unstructured":"Bjureberg J, Dahlin M, Carlborg A, Edberg H, Haglund A, Runeson B. Columbia-Suicide Severity Rating Scale Screen Version: initial screening for suicide risk in a psychiatric emergency department. Psychol Med. 2021;52(16):1\u20139.","journal-title":"Psychol Med"},{"key":"8238_CR27","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/1477-7525-2-12","volume":"2","author":"MJ Atkinson","year":"2004","unstructured":"Atkinson MJ, Sinha A, Hass SL, Colman SS, Kumar RN, Brod M, et al. Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease. Health Qual Life Outcomes. 2004;2:12.","journal-title":"Health Qual Life Outcomes."},{"issue":"10","key":"8238_CR28","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1001\/archinte.166.10.1092","volume":"166","author":"RL Spitzer","year":"2006","unstructured":"Spitzer RL, Kroenke K, Williams JB, L\u00f6we B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med. 2006;166(10):1092\u20137.","journal-title":"Arch Intern Med"},{"key":"8238_CR29","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.eurpsy.2018.05.006","volume":"53","author":"M Mohebbi","year":"2018","unstructured":"Mohebbi M, Dodd S, Dean OM, Berk M. Patient centric measures for a patient centric era: Agreement and convergent between ratings on The Patient Global Impression of Improvement (PGI-I) scale and the Clinical Global Impressions - Improvement (CGI-S) scale in bipolar and major depressive disorder. Eur Psychiatry. 2018;53:17\u201322.","journal-title":"Eur Psychiatry"},{"issue":"5","key":"8238_CR30","doi-asserted-by":"publisher","first-page":"353","DOI":"10.2165\/00019053-199304050-00006","volume":"4","author":"MC Reilly","year":"1993","unstructured":"Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics. 1993;4(5):353\u201365.","journal-title":"Pharmacoeconomics"},{"key":"8238_CR31","unstructured":"NCCIH Clinical Research Toolbox. National Centre for Complementary and Integrative Health, National Institute for Health, Bethesda, MD. 2018. https:\/\/nccih.nih.gov\/grants\/toolbox. Accessed 22 Aug 2018."},{"issue":"2","key":"8238_CR32","doi-asserted-by":"publisher","first-page":"109","DOI":"10.2165\/00002018-199920020-00002","volume":"20","author":"EG Brown","year":"1999","unstructured":"Brown EG, Wood L, Wood S. The medical dictionary for regulatory activities (MedDRA). Drug Saf. 1999;20(2):109\u201317.","journal-title":"Drug Saf"},{"issue":"2","key":"8238_CR33","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","volume":"42","author":"PA Harris","year":"2009","unstructured":"Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)\u2013a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377\u201381.","journal-title":"J Biomed Inform"},{"key":"8238_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbi.2019.103208","volume":"95","author":"PA Harris","year":"2019","unstructured":"Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O\u2019Neal L, et al. The REDCap consortium: Building an international community of software platform partners. J Biomed Inform. 2019;95: 103208.","journal-title":"J Biomed Inform"},{"issue":"12","key":"8238_CR35","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1111\/j.1360-0443.2003.00486.x","volume":"98","author":"C Day","year":"2003","unstructured":"Day C, Topp L. Safety in drug and alcohol research. Addiction. 2003;98(12):1641\u20133.","journal-title":"Addiction"},{"issue":"3","key":"8238_CR36","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1001\/archpsyc.61.3.310","volume":"61","author":"R Gueorguieva","year":"2004","unstructured":"Gueorguieva R, Krystal JH. Move over ANOVA: progress in analyzing repeated-measures data and its reflection in papers published in the Archives of General Psychiatry. Arch Gen Psychiatry. 2004;61(3):310\u20137.","journal-title":"Arch Gen Psychiatry"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-024-08238-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-024-08238-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-024-08238-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,22]],"date-time":"2024-06-22T01:02:15Z","timestamp":1719018135000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-024-08238-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,22]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["8238"],"URL":"https:\/\/doi.org\/10.1186\/s13063-024-08238-y","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,22]]},"assertion":[{"value":"1 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This trial has been approved by the Joint University of Wollongong and Illawarra Shoalhaven Local Health District Health Medical Human Research Ethics Committee (2021\/ETH12037), and the North Metropolitan Area Mental Health Services Human Research Ethics Committee (PRN RGS0000005312). All participants provide informed consent prior to participation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate {24}"}},{"value":"All participants provide informed consent which includes consent to publish the data in a way that they cannot be identified. The participant information sheet and informed consent form are available from the authors on request.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication {32}"}},{"value":"MB has received grants from Meat and Livestock Board, Woolworths, Bristol Myers Squibb, Eli Lilly, Glaxo SmithKline, Organon, Novartis, Mayne Pharma, Servier; received speaker support from Lundbeck, Controversias Barcelona, Servier, Medisquire, Janssen, Medplan, Abbott India, Sandoz, Astra Zeneca Bristol Myers Squibb, Eli Lilly, Glaxo SmithKline, Pfizer, Sanofi-Synthelabo Solvay, and Wyeth; and, consulted to Milken Institute AstraZeneca Bristol Myers Squibb Eli Lilly Bioadvantex Merck Glaxo SmithKline Lundbeck Janssen Cilag Servier. LD has received untied educational grants for the study of new opioid medications in Australia from Indivior and Seqirus. MF has received unrestricted educational grants for studies of opioid medications in Australia from Indivior, Mundipharma and Seqirus. OD has received grant support from Lilly and Servier, and in-kind support from BioMedica Nutracuticals, NutritionCare and Bioceuticals. SA has received speaker support from Camurus, Gilead, Janssen and Servier. Other authors have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests {28}"}}],"article-number":"408"}}